Building a Fully-Integrated Biotech in Precision Medicine Oncology
Foundational First-in-Class Pipeline Enables a Leading Precision Medicine Oncology Franchise
Darovasertib Registration-Enabling Trial with Potential Accelerated Approval in HLA-A2(-) MUM is tractable for
commercial execution and provides path to potential product revenue to reinvest in broad first-in-class pipeline
Emerging Pipeline of Potential First-in-Class Precision Medicine Oncology Programs with large addressable solid tumor
patient populations, including Daro (Ph 2 Primary UM), IDE397 (Ph 2), IDE161 (Ph 1), GSK101 (Ph1) and
Werner Helicase (Development Candidate H2 2023)
Strong Balance Sheet with ~$510 M anticipated to fund operations into 2027 1,2 and opportunity for milestones
Validating Pharma Partnerships and Collaborations include clinical collaborations for combination therapies with Pfizer
and Amgen and strategic collaboration with GSK with ~$1 billion milestones/program
CLINICAL
Ph2/3 - Daro + Crizo in Metastatic UM
3
Ph2 - Darovasertib (PKC) in Primary UM
Ph 2 IDE397 (MAT2A)
Ph 1 - IDE397 (MAT2A) + AMG 193 (PRMT5MTA) 3
Ph 1 – IDE161 (PARG)
Ph 1- GSK101 (Pol Theta Helicase) 4
2023 Foundation: 4 Clinical Programs
(1) Includes aggregate of $510.1 M cash, cash equivalents and marketable securities as of June 30, 2023
IDEAYA Form 10-Q dated August 10, 2023 as filed with the U.S. Securities and Exchange Commission
DEVELOPMENT CANDIDATES
Werner Helicase - Dev Candidate H2 2023 4
PRECLINICAL
Targeting 2 IND Filings (2025+)
5 Clinical Programs
7 Clinical Programs
(2)
(3)
Clinical Trial Collaboration and Supply Agreements, independently with Pfizer (Darovasertib + Crizotinib) and Amgen (IDE397 + AMG193); IDEAYA retains all commercial rights
(4)
GSK101 Pol Theta Program Cost Share = 100% GSK with ~$1B Milestones and WW Royalties; Werner Helicase Program Cost Share = 80% GSK / 20% IDEAYA with ~$1B Milestones, 50/50 US Profit Share and Ex-US Royalties
41
IDEAVA
BIOSCIENCESView entire presentation